"Over $1 Billion Spent on Weight Loss and Diabetes Drug Ads"

Drugmakers spent over $1 billion on advertisements for weight loss and diabetes drugs in 2023, reflecting the competitive market for these treatments. Novo Nordisk's drugs, Ozempic and Wegovy, have been heavily promoted, contributing to the surge in ad spending. Initial data for 2024 suggests that ad spending for these drugs remains strong. Additionally, the FDA has approved an AI-powered diagnostic tool for sepsis, developed by health tech startup Prenosis, which aims to help clinicians assess a patient's risk of sepsis more effectively.